Development and Validation of an Immune-Related Gene Pairs Signature in Grade II/III Glioma

References

• Wesseling P, Capper D. WHO 2016 Classification of gliomas. Neuropathol Appl Neurobiol. 2018;44(2):139–150. doi:10.1111/nan.12432
   PubMed Web of Science ®Google Scholar
• Claus EB, Walsh KM, Wiencke JK, et al. Survival and low-grade glioma: the emergence of genetic information. Neurosurg Focus. 2015;38(1):E6. doi:10.3171/2014.10.FOCUS12367
   PubMed Web of Science ®Google Scholar
• Yan Y, Li Z, Zeng S, Wang X, Gong Z, Xu Z. FGFR2-mediated phosphorylation of PTEN at tyrosine 240 contributes to the radioresistance of glioma. J Cell Commun Signal. 2019;13(3):279–280. doi:10.1007/s12079-019-00518-6
   PubMed Web of Science ®Google Scholar
• Yan Y, Xu Z, Dai S, Qian L, Sun L, Gong Z. Targeting autophagy to sensitive glioma to temozolomide treatment. J Exp Clin Cancer Res. 2016;35:23. doi:10.1186/s13046-016-0303-5
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology–Haarlem consensus guidelines for nervous system tumor classification and grading. Brain Pathol. 2014;24(5):429–435. doi:10.1111/bpa.12171
   PubMed Web of Science ®Google Scholar
• Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas. Acta Neuropathol. 2010;120(6):707–718. doi:10.1007/s00401-010-0781-z
   PubMed Web of Science ®Google Scholar
• Louis DN, Perry A, Reifenberger G, et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary. Acta Neuropathol. 2016;131(6):803–820. doi:10.1007/s00401-016-1545-1
   PubMed Web of Science ®Google Scholar
• Wick W, Meisner C, Hentschel B, et al. Prognostic or predictive value of MGMT promoter methylation in gliomas depends on IDH1 mutation. Neurology. 2013;81(17):1515–1522. doi:10.1212/WNL.0b013e3182a95680
   PubMed Web of Science ®Google Scholar
• Wu T, Dai Y. Tumor microenvironment and therapeutic response. Cancer Lett. 2017;387:61–68. doi:10.1016/j.canlet.2016.01.043
   PubMed Web of Science ®Google Scholar
• Ni J, Liu S, Qi F, et al. Screening TCGA database for prognostic genes in lower grade glioma microenvironment. Ann Transl Med. 2020;8(5):209. doi:10.21037/atm.2020.01.73
   PubMed Web of Science ®Google Scholar
• Yoshihara K, Shahmoradgoli M, Martinez E, et al. Inferring tumour purity and stromal and immune cell admixture from expression data. Nat Commun. 2013;4:2612. doi:10.1038/ncomms3612
   PubMed Web of Science ®Google Scholar
• Shah N, Wang P, Wongvipat J, et al. Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife. 2017;6:215.
   Web of Science ®Google Scholar
• Alonso MH, Ausso S, Lopez-Doriga A, et al. Comprehensive analysis of copy number aberrations in microsatellite stable colon cancer in view of stromal component. Br J Cancer. 2017;117(3):421–431. doi:10.1038/bjc.2017.208
   PubMed Web of Science ®Google Scholar
• Gieryng A, Pszczolkowska D, Walentynowicz KA, Rajan WD, Kaminska B. Immune microenvironment of gliomas. Lab Invest. 2017;97(5):498–518. doi:10.1038/labinvest.2017.19
   PubMed Web of Science ®Google Scholar
• Vismara MFM, Donato A, Malara N, Presta I, Donato G. Immunotherapy in gliomas: are we reckoning without the innate immunity? Int J Immunopathol Pharmacol. 2019;33:2058738419843378. doi:10.1177/2058738419843378
   Web of Science ®Google Scholar
• Simonelli M, Persico P, Perrino M, et al. Checkpoint inhibitors as treatment for malignant gliomas: “A long way to the top”. Cancer Treat Rev. 2018;69:121–131. doi:10.1016/j.ctrv.2018.06.016
   PubMed Web of Science ®Google Scholar
• Ascierto ML, Kmieciak M, Idowu MO, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012;131(3):871–880. doi:10.1007/s10549-011-1470-x
   PubMed Web of Science ®Google Scholar
• Kim K, Jeon S, Kim TM, Jung CK. Immune Gene Signature Delineates a Subclass of Papillary Thyroid Cancer with Unfavorable Clinical Outcomes. Cancers. 2018;10(12):494. doi:10.3390/cancers10120494
   PubMed Web of Science ®Google Scholar
• Shen S, Wang G, Zhang R, et al. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer. EBioMedicine. 2019;40:318–326. doi:10.1016/j.ebiom.2018.12.054
   PubMed Web of Science ®Google Scholar
• Yang W, Lai Z, Li Y, et al. Immune signature profiling identified prognostic factors for gastric cancer. Chin J Cancer Res. 2019;31(3):463–470. doi:10.21147/j.issn.1000-9604.2019.03.08
   PubMed Web of Science ®Google Scholar
• Zhang M, Wang X, Chen X, Zhang Q, Hong J. Novel Immune-Related Gene Signature for Risk Stratification and Prognosis of Survival in Lower-Grade Glioma. Front Genet. 2020;11:363. doi:10.3389/fgene.2020.00363
   PubMed Web of Science ®Google Scholar
• Cheng W, Ren X, Zhang C, et al. Bioinformatic profiling identifies an immune-related risk signature for glioblastoma. Neurology. 2016;86(24):2226–2234. doi:10.1212/WNL.0000000000002770
   PubMed Web of Science ®Google Scholar
• Leek JT, Scharpf RB, Bravo HC, et al. Tackling the widespread and critical impact of batch effects in high-throughput data. Nat Rev Genet. 2010;11(10):733–739. doi:10.1038/nrg2825
   PubMed Web of Science ®Google Scholar
• Xiong Y, Liu L, Bai Q, et al. Individualized immune-related gene signature predicts immune status and oncologic outcomes in clear cell renal cell carcinoma patients. Urol Oncol. 2020;38(1):7.e1–7.e8. doi:10.1016/j.urolonc.2019.09.014
   PubMed Web of Science ®Google Scholar
• Sun XY, Yu SZ, Zhang HP, Li J, Guo WZ, Zhang SJ. A signature of 33 immune-related gene pairs predicts clinical outcome in hepatocellular carcinoma. Cancer Med. 2020;9(8):2868–2878. doi:10.1002/cam4.2921
   PubMed Web of Science ®Google Scholar
• Chen W, Ou M, Tang D, Dai Y, Du W. Identification and Validation of Immune-Related Gene Prognostic Signature for Hepatocellular Carcinoma. J Immunol Res. 2020;2020:5494858. doi:10.1155/2020/5494858
   PubMed Web of Science ®Google Scholar
• Wu J, Zhao Y, Zhang J, Wu Q, Wang W. Development and validation of an immune-related gene pairs signature in colorectal cancer. Oncoimmunology. 2019;8(7):1596715. doi:10.1080/2162402X.2019.1596715
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhu P, Tong Y, et al. An immune-related gene pairs signature predicts overall survival in serous ovarian carcinoma. Onco Targets Ther. 2019;12:7005–7014. doi:10.1152/ajplegacy.1975.229.6.1641
   PubMed Web of Science ®Google Scholar
• Li B, Cui Y, Diehn M, Development LR. Validation of an Individualized Immune Prognostic Signature in Early-Stage Nonsquamous Non-Small Cell Lung Cancer. JAMA Oncol. 2017;3(11):1529–1537. doi:10.1001/jamaoncol.2017.1609
   PubMed Web of Science ®Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Newman AM, Liu CL, Green MR, et al. Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015;12(5):453–457. doi:10.1038/nmeth.3337
   PubMed Web of Science ®Google Scholar
• Chen H, Boutros PC. VennDiagram: a package for the generation of highly-customizable Venn and Euler diagrams in R. BMC Bioinform. 2011;12:35. doi:10.1186/1471-2105-12-35
   PubMed Web of Science ®Google Scholar
• Kiran M, Chatrath A, Tang X, Keenan DM, Dutta A, Prognostic A. Signature for Lower Grade Gliomas Based on Expression of Long Non-Coding RNAs. Mol Neurobiol. 2019;56(7):4786–4798. doi:10.1007/s12035-018-1416-y
   PubMed Web of Science ®Google Scholar
• Deng X, Lin D, Zhang X, et al. Profiles of immune-related genes and immune cell infiltration in the tumor microenvironment of diffuse lower-grade gliomas. J Cell Physiol. 2020;235(10):7321–7331. doi:10.1002/jcp.29633
   PubMed Web of Science ®Google Scholar
• Persano L, Pistollato F, Rampazzo E, et al. BMP2 sensitizes glioblastoma stem-like cells to Temozolomide by affecting HIF-1alpha stability and MGMT expression. Cell Death Dis. 2012;3:e412. doi:10.1038/cddis.2012.153
   PubMed Web of Science ®Google Scholar
• Ishihara E, Takahashi S, Fukaya R, Ohta S, Yoshida K, Toda M. Identification of KLRC2 as a candidate marker for brain tumor-initiating cells. Neurol Res. 2019;41(11):1043–1049. doi:10.1080/01616412.2019.1672390
   PubMed Web of Science ®Google Scholar
• Uemae Y, Ishikawa E, Osuka S, et al. CXCL12 secreted from glioma stem cells regulates their proliferation. J Neurooncol. 2014;117(1):43–51. doi:10.1007/s11060-014-1364-y
   PubMed Web of Science ®Google Scholar
• Fecci PE, Mitchell DA, Whitesides JF, et al. Increased regulatory T-cell fraction amidst a diminished CD4 compartment explains cellular immune defects in patients with malignant glioma. Cancer Res. 2006;66(6):3294–3302. doi:10.1158/0008-5472.CAN-05-3773
   PubMed Web of Science ®Google Scholar
• Alexiou GA, Vartholomatos G, Karamoutsios A, Batistatou A, Kyritsis AP, Voulgaris S. Circulating progenitor cells: a comparison of patients with glioblastoma or meningioma. Acta Neurol Belg. 2013;113(1):7–11. doi:10.1007/s13760-012-0097-y
   PubMed Web of Science ®Google Scholar
• Wainwright DA, Dey M, Chang A, Lesniak MS. Targeting Tregs in Malignant Brain Cancer: overcoming IDO. Front Immunol. 2013;4:116. doi:10.3389/fimmu.2013.00116
   PubMed Web of Science ®Google Scholar
• Zhang X, Ping S, Zhang R, et al. Development and validation of an immune-related gene pairs signature in lower-grade glioma. 2020. doi:10.21203/rs.3.rs-35147/v1
   Google Scholar